NYSE - Delayed Quote USD

Boston Scientific Corporation (BSX)

Compare
81.14 -0.65 (-0.79%)
At close: September 3 at 4:00 PM EDT
80.54 -0.60 (-0.74%)
After hours: September 3 at 7:55 PM EDT
Loading Chart for BSX
DELL
  • Previous Close 81.79
  • Open 81.70
  • Bid 79.89 x 1000
  • Ask 82.49 x 800
  • Day's Range 80.79 - 82.07
  • 52 Week Range 48.35 - 82.10
  • Volume 5,456,468
  • Avg. Volume 5,553,114
  • Market Cap (intraday) 120.446B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 65.97
  • EPS (TTM) 1.23
  • Earnings Date Oct 24, 2024 - Oct 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 87.84

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

www.bostonscientific.com

48,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BSX

View More

Research Reports: BSX

View More

Performance Overview: BSX

Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BSX
40.36%
S&P 500
15.91%

1-Year Return

BSX
51.32%
S&P 500
22.44%

3-Year Return

BSX
80.07%
S&P 500
21.86%

5-Year Return

BSX
89.89%
S&P 500
88.93%

Compare To: BSX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BSX

View More

Valuation Measures

Annual
As of 9/3/2024
  • Market Cap

    119.49B

  • Enterprise Value

    127.51B

  • Trailing P/E

    65.97

  • Forward P/E

    29.76

  • PEG Ratio (5yr expected)

    2.00

  • Price/Sales (ttm)

    7.88

  • Price/Book (mrq)

    5.87

  • Enterprise Value/Revenue

    8.37

  • Enterprise Value/EBITDA

    34.96

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.00%

  • Return on Assets (ttm)

    4.81%

  • Return on Equity (ttm)

    9.32%

  • Revenue (ttm)

    15.23B

  • Net Income Avi to Common (ttm)

    1.83B

  • Diluted EPS (ttm)

    1.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.91B

  • Total Debt/Equity (mrq)

    53.06%

  • Levered Free Cash Flow (ttm)

    1.61B

Research Analysis: BSX

View More

Company Insights: BSX

People Also Watch